Jackson Creek Investment Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Jackson Creek Investment Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.74M	Sell	6,037 -2,276	-27%	-$536K	0.58%	25
2026 Q1	$1.66M	Hold	8,313	–	–	0.49%	91
2025 Q4	$1.57M	Sell	8,313 -6,157	-43%	-$1.18M	0.46%	100
2025 Q3	$2.56M	Sell	14,470 -6	-0%	-$892	0.74%	6
2025 Q2	$1.65M	Buy	14,476 +2,051	+17%	+$219K	0.44%	109
2025 Q1	$1.31M	Sell	12,425 -4,522	-27%	-$511K	0.42%	129
2024 Q4	$1.82M	Sell	16,947 -529	-3%	-$59.8K	0.55%	31
2024 Q3	$1.75M	Buy	17,476 +3,876	+29%	+$390K	0.52%	45
2024 Q2	$1.15M	Sell	13,600 -24	-0.2%	-$1.91K	0.42%	81
2024 Q1	$996K	Sell	13,624 -29	-0.2%	-$2.14K	0.36%	158
2023 Q4	$975K	Sell	13,653 -4	-0%	-$236	0.37%	136
2023 Q3	$818K	Sell	13,657 -10	-0.1%	-$658	0.35%	155
2023 Q2	$985K	Buy	13,667 +941	+7%	+$70.6K	0.39%	92
2023 Q1	$936K	Buy	+12,726	New	+$905K	0.39%	84
2022 Q4	–	Sell	-15,429	Closed	-$829K	–	340
2022 Q3	$829K	Buy	+15,429	New	+$907K	0.39%	116
2020 Q4	–	Sell	-11,671	Closed	-$694K	–	332
2020 Q3	$694K	Buy	+11,671	New	+$796K	0.31%	175

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jackson Creek Investment Advisors's LGND Position: Q2 2026 in Review

Jackson Creek Investment Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 27% in Q2 2026, selling an estimated $536K and leaving 6,037 shares worth $1.74M. The position accounts for 0.58% of the portfolio, ranked #25.

Jackson Creek Investment Advisors first reported a position in LGND in Q3 2020 and has held it in 16 quarters since. The position peaked at $2.56M in Q3 2025. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Jackson Creek Investment Advisors held 6,037 shares of Ligand Pharmaceuticals worth $1.74M as of Q2 2026.
Jackson Creek Investment Advisors sold 2,276 Ligand Pharmaceuticals shares in Q2 2026, an estimated $536K.
Ligand Pharmaceuticals made up 0.58% of Jackson Creek Investment Advisors's portfolio in Q2 2026, its #25 holding.
Jackson Creek Investment Advisors first reported a position in Ligand Pharmaceuticals in Q3 2020 and has held it in 16 quarters since.
Jackson Creek Investment Advisors's Ligand Pharmaceuticals position peaked at $2.56M in Q3 2025.
416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Jackson Creek Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.